Bavarian Nordic expects imminent European monkeypox green light

Experts agreed Friday to recommend adding monkeypox to the label of the Danish biotech firm’s vaccine, meaning official EU approval could be right around the corner, says a Bavarian representative.

Photo: Sven Hoppe/AP/Ritzau Scanpix

Bavarian Nordic is counting on the imminent European authorization to expand smallpox vaccine Imvanex’s label to include monkeypox, according to Head of Investor Relations at the firm Rolf Sass Sørensen.

On Friday morning, the vaccine maker received a positive opinion to extend the vaccine’s indication to include monkeypox from the European Medicines Agency’s (EMA) expert committee, the CHMP. The vaccine will now face the EU Commission, which has the final say in matters of drug authorization.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs